HK1110200A1 - Remedy for hyperlipemia - Google Patents

Remedy for hyperlipemia

Info

Publication number
HK1110200A1
HK1110200A1 HK08100666.5A HK08100666A HK1110200A1 HK 1110200 A1 HK1110200 A1 HK 1110200A1 HK 08100666 A HK08100666 A HK 08100666A HK 1110200 A1 HK1110200 A1 HK 1110200A1
Authority
HK
Hong Kong
Prior art keywords
hyperlipemia
remedy
pitavastatin
ezetimibe
hypercholesterolemia
Prior art date
Application number
HK08100666.5A
Other languages
English (en)
Inventor
Taro Aoki
Hiroyuki Yamazaki
Takashi Maejima
Original Assignee
Kowa Co
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35944235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1110200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kowa Co, Nissan Chemical Ind Ltd filed Critical Kowa Co
Publication of HK1110200A1 publication Critical patent/HK1110200A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK08100666.5A 2004-08-31 2008-01-18 Remedy for hyperlipemia HK1110200A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60552504P 2004-08-31 2004-08-31
US10/997,878 US20060046996A1 (en) 2004-08-31 2004-11-29 Method for treating hyperlipidemia
PCT/JP2005/015756 WO2006025378A1 (ja) 2004-08-31 2005-08-30 高脂血症治療剤

Publications (1)

Publication Number Publication Date
HK1110200A1 true HK1110200A1 (en) 2008-07-11

Family

ID=35944235

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08100666.5A HK1110200A1 (en) 2004-08-31 2008-01-18 Remedy for hyperlipemia

Country Status (13)

Country Link
US (2) US20060046996A1 (xx)
EP (1) EP1785137B1 (xx)
JP (1) JP4886516B2 (xx)
KR (1) KR101244508B1 (xx)
CN (1) CN101010080B (xx)
AT (1) ATE489093T1 (xx)
CY (1) CY1111150T1 (xx)
DE (1) DE602005024981D1 (xx)
ES (1) ES2354366T3 (xx)
HK (1) HK1110200A1 (xx)
PL (1) PL1785137T3 (xx)
PT (1) PT1785137E (xx)
WO (1) WO2006025378A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
WO2004091660A1 (ja) * 2003-04-17 2004-10-28 Kowa Co., Ltd. Lklf/klf2遺伝子発現促進剤
WO2005061452A1 (en) * 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
TW200619204A (en) * 2004-12-10 2006-06-16 Kowa Co Method for reduction, stabilization and prevention of rupture of lipid rich plaque
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR060623A1 (es) * 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011088055A2 (en) * 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
TWI586380B (zh) * 2013-12-18 2017-06-11 夢製藥公司 包含HMG-CoA還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑
US10413543B2 (en) * 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
JPWO2020178878A1 (xx) * 2019-03-01 2020-09-10
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5185328A (en) * 1987-08-20 1993-02-09 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
US5854259A (en) * 1987-08-20 1998-12-29 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6465477B1 (en) * 1997-08-18 2002-10-15 Kowa Company, Ltd. Stable pharmaceutical composition
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CA2594433C (en) * 2005-01-10 2014-12-30 Cortendo Invest Ab Compositions comprising the 2s,4r ketoconazole enantiomer for treating diabetes, metabolic syndrome and other conditions

Also Published As

Publication number Publication date
US20070032467A1 (en) 2007-02-08
PL1785137T3 (pl) 2011-04-29
CN101010080B (zh) 2011-02-09
EP1785137A1 (en) 2007-05-16
EP1785137A4 (en) 2007-12-19
CY1111150T1 (el) 2015-06-11
ATE489093T1 (de) 2010-12-15
US7459447B2 (en) 2008-12-02
WO2006025378A1 (ja) 2006-03-09
KR101244508B1 (ko) 2013-03-18
EP1785137B1 (en) 2010-11-24
JP4886516B2 (ja) 2012-02-29
KR20070047766A (ko) 2007-05-07
US20060046996A1 (en) 2006-03-02
PT1785137E (pt) 2010-12-23
CN101010080A (zh) 2007-08-01
JPWO2006025378A1 (ja) 2008-05-08
ES2354366T3 (es) 2011-03-14
DE602005024981D1 (de) 2011-01-05

Similar Documents

Publication Publication Date Title
HK1110200A1 (en) Remedy for hyperlipemia
NO20050073L (no) Ringsubstituerte difenylazetidinoner, deres fremstilling, deres anvendelse samt legemidler inneholdende forbindelsene
CY2019030I1 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
AU2003251563A1 (en) Implatable or insertable medical devices for controlled delivery of a therapeutic agent
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2005046662A3 (en) Hdl-boosting combination therapy complexes
WO2005002515A3 (en) Delivery of therapeutic compounds to the brain and other tissues
MY176938A (en) 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d] pyrimidin-2-one compounds and prodrugs thereof
ATE257480T1 (de) Bicyclische pyrrolylamide als glycogenphosphorylase-inhibitoren
NO20020811L (no) Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler
WO2005044192A3 (en) Triazole compounds and uses related thereto
WO2009005269A3 (en) Pharmaceutical composition for preventintion and treatment of restenosis comprising isoxazole derivatives
AU2002366355A1 (en) SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
HK1137142A1 (en) Drug for treatment of influenza
ATE360633T1 (de) N-substituierte hydromorphone und ihre anwendung
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
EP1753425A4 (en) THERAPEUTIC AGENT COMPRISING A NICOTINIC ACID OR DERIVATIVES AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER
AU2001263383A1 (en) Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer
WO2006033891A3 (en) Compounds for the treatment of dyslipidemia and other lipid disorders
AU2003210659A1 (en) Combination therapy for treatment of hiv infection
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
TW200635592A (en) Pyridyl-substituted spiro-hydantoin compounds and use thereof
WO2003089449A3 (fr) Composes aminoalkylsteroles avec activite anti-tumeur et neuroprotective
SE0004827D0 (sv) Therapeutic compounds
BRPI0417747A (pt) uso de compostos orgánicos

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210827